key: cord-0908552-165evsq1
authors: Vanhulle, Emiel; Stroobants, Joren; Provinciael, Becky; Camps, Anita; Noppen, Sam; Maes, Piet; Vermeire, Kurt
title: SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening
date: 2022-02-14
journal: bioRxiv
DOI: 10.1101/2022.02.13.480238
sha: 4a6f1fc7c171da3b81c3f87db9e1bd4af7cb44ad
doc_id: 908552
cord_uid: 165evsq1

Despite the great success of the administered vaccines against SARS-CoV-2, the virus can still spread, as evidenced by the current circulation of the highly contagious Omicron variant. This emphasizes the additional need to develop effective antiviral countermeasures. In the context of early preclinical studies for antiviral assessment, robust cellular infection systems are required to screen drug libraries. In this study, we reported the implementation of a human glioblastoma cell line, stably expressing ACE2, in a SARS-CoV-2 cytopathic effect (CPE) reduction assay. These glioblastoma cells, designated as U87.ACE2+, expressed ACE2 and cathepsin B abundantly, but had low cellular levels of TMPRSS2 and cathepsin L. The U87.ACE2+ cells fused highly efficiently and quickly with SARS-CoV-2 spike expressing cells. Furthermore, upon infection with SARS-CoV-2 wild-type virus, the U87.ACE2+ cells displayed rapidly a clear CPE that resulted in complete cell lysis and destruction of the cell monolayer. By means of several readouts we showed that the U87.ACE2+ cells actively replicate SARS-CoV-2. Interestingly, the U87.ACE2+ cells could be successfully implemented in an MTS-based colorimetric CPE reduction assay, providing IC50 values for Remdesivir in the low nanomolar range. Lastly, the U87.ACE2+ cells were consistently permissive to all tested SARS-CoV-2 variants of concern, including the current Omicron variant. Thus, ACE2 expressing glioblastoma cells are highly permissive to SARS-CoV-2 with productive viral replication and with the induction of a strong CPE that can be utilized in high-throughput screening platforms.

SARS-CoV-2, the causative agent of COVID-19, has quickly spread around the world, 48 leading to over 400 million confirmed cases and more than 5.8 million deaths worldwide 49 as of February 11, 2022 (https://covid19.who.int/). Despite the great success of the 50 current vaccines against SARS-CoV-2, we still cannot control the spread of new 51 variants and/or prevent re-infections. This emphasizes the urgent need to develop 52 effective antiviral countermeasures. 53

Major efforts are ongoing to develop novel therapeutics for COVID-19 treatment and/or 54 effective prophylactic approaches to prevent viral spread (1). In the context of early 55 preclinical studies for antiviral assessment, screening platforms for drug libraries rely 56 on the use of robust cellular infection systems, mostly based on immortalized cell lines 57 originating from respiratory, but most often non-respiratory, tissues (2). In fact, many 58 initial screenings for SARS-CoV-2 antivirals have largely utilized the African green 59 monkey kidney cell line Vero E6 as the host cell. However, it is known that Vero E6 60 cells exploit intrinsic nonspecific endocytic mechanisms for virus uptake and viral entry 61

(2). Furthermore, these cells have a low expression of angiotensin converting enzyme 62 12 effect and GFP expression were scored in a blinded manner at different time points 230 post infection, and the supernatants were collected and stored at -20 °C. 231 trypsin (0.25 %) was added and plates were incubated for 3' at 37 °C to detach the 243 cells from the plate, followed by the addition of cold culture medium with 2 % FCS. 244

Next, cells were resuspended, transferred to tubes and samples were centrifuged in a 245 cooled centrifuge (4 °C) at 500 g for 5'. After removal of the supernatant, cells were 246 fixed and permeabilized by the addition of 250 µL of BD Cytofix/Cytoperm buffer and 247 incubated at 4 °C for 20'. Samples were washed twice with Perm/Wash buffer before 248 the addition of the primary (anti-Nucleocapsid) antibody (0.3 µg per sample with SARS-CoV-2 (data not shown). Therefore, we determined the cellular expression 281 of ACE2, known as the main receptor for SARS-CoV-2 (3-6). As shown in Figure 1A , 282 basal level of ACE2 was undetectable in U87 cells, as measured by immunoblotting, 283 whereas in control Calu-3 cells traces of ACE2 protein could be visualized. In contrast, 284

Vero E6 cells expressed endogenous ACE2 at detectable amounts. Thus, we 285 subsequently introduced the coding sequence for ACE2 in the U87 cells to enhance 286 their sensitivity to SARS-CoV-2. Briefly, cells were stably transduced with a lentiviral 287 vector that encodes for ACE2. After clonal expansion, the cells -designated as 288 U87.ACE2 + -were evaluated for their ACE2 protein levels. As shown in Figure 1B , 289 the U87.ACE2 + cells were successfully transduced with ACE2 as evidenced by the 290 very dense protein band on the immunoblot that corresponded to the ACE2 receptor. 291 Furthermore, passaging of the cells for several months did not impact the high ACE2 292 expression level (Figure 1B) , which demonstrated that the U87.ACE2 + cells were 293 stably expressing high amounts of the SARS-CoV-2 receptor of interest. 294

Following ACE2 binding, the spike protein also needs priming by cellular proteases 295 before membrane fusion and cellular entry of the virus can take place (3, 8, 10, 11) . 296 15 Thus, we additionally measured the expression of TMPRSS2 and CTSB/L in the 297 U87.ACE2 + cells. As multiple attempts with different antibodies did not result in 298 successful and reliable immunoblotting of TMPRSS2, we chose quantitative PCR 299 (qPCR) as an alternative for the detection of endogenous TMPRSS2. As shown in 300 Figure 1C , U87.ACE2 + cells had detectable mRNA levels of TMPRSS2, comparable 301 to that of A549 cells, but clearly less than what is measured in Calu-3 cells. In line with 302 other reports (2, 8), our qPCR data verified that Vero E6 are deficient in TMPRSS2. In 303 addition, immunoblots of CTSB demonstrated an enormous endogenous expression 304 of this protease in the U87.ACE2 + cells, that outranged CTSB protein levels in A549, 305

Calu-3 and Vero E6 ( Figure 1D ). In contrast to the very weak detection of CTSB, Vero 306 E6 cells expressed CTSL at high levels, as evidenced by the intense protein band that 307 corresponded with the mature non-glycosylated form of CTSL ( Figure 1D) . 308

Immunoblotting results for CTSL in the U87.ACE2 + cells revealed detectable 309 endogenous expression of CTSL at a level comparable to that measured in the A549 310 cells ( Figure 1D ). However, in the U87.ACE2 + cells the glycosylated mature form of 311 CTSL was mainly detected. Thus, the high abundance of CTSB and detectable levels 312 of CTSL suggest the potential for a endocytic pathway for SARS-CoV-2 entry in the 313 U87.ACE2 + cells. 314

316 Having a U87.ACE2 + cell line established, we next determined if these cells express a 317 functional ACE2 receptor that can activate the SARS-CoV-2 Spike (S) protein for 318 membrane fusion. Therefore, we assessed the cell-cell fusion capability of the 319 U87.ACE2 + cells with cells expressing the S protein of SARS-CoV-2 (see scheme in 320 Figure 2A ). Briefly, HEK293T cells were transfected with a plasmid encoding for a 321 codon-optimized S protein of SARS-CoV-2 (Wuhan strain). In parallel, U87.ACE2 + 322 cells were plated in a 96-well plate to generate a confluent cell layer. Next, the 323 transfected HEK293T cells, expressing the S protein at their cell surface in sufficient 324 amount ( Figure 2B) , were administered to the U87.ACE2 + cells. As depicted in Figure  325 2C, a successful fusion between the U87.ACE2 + cells and S-expressing HEK293T 326 cells was obtained, leading to the formation of many fused multinucleated giant cells 327 

CoV-2 335 Next, we determined if the U87.ACE2 + cells could be infected with wild-type SARS-336

CoV-2 virus. Therefore, the U87.ACE2 + cells were exposed to SARS-CoV-2 (strain 337 20A.EU2) and microscopically evaluated for cytopathic effect (CPE). As depicted in 338 Figure 3B ). In parallel, cells were exposed to a recombinant GFP-expressing SARS-344

CoV-2 variant (Wuhan strain) (17). As shown in Figure 3C , a productive SARS-CoV-345 2 infection was obtained cells when the U87.ACE2 + cells were exposed to a MOI of 3, 346 as evidenced by the profound GFP expression at 22 h p.i. Further dilution of the virus 347 stock resulted in a gradual lower infectivity rate of the cells (Figure 3C) Having successfully developed a cell line that is highly permissive to SARS-CoV-2 and 366 that produces full-blown CPE, we next determined if this cell line could be implemented 367 in an antiviral screening platform. Thus, the U87.ACE2 + cells were seeded in 96-well 368 plates, treated with test compounds, and exposed to SARS-CoV-2. As proof-of-369 concept, we first tested Remdesivir (GS-5734), a nucleotide analog prodrug that 370 18 inhibits the SARS-CoV-2 RNA dependent RNA polymerase (RdRp) (2, (22) (23) (24) (25) , and a 371 spike-neutralizing antibody (R001), acting as an SARS-CoV-2 entry inhibitor (16). At 2 372 days p.i., samples were collected and analyzed, either by flow cytometry (Figure 5A ) 373 or by duplex RT-qPCR ( Figure 5B) Finally, in view of a high-throughput antiviral screening application, we explored a 382 colorimetric read-out of the SARS-CoV-2 infected U87.ACE2 + cells. First, a density 383 range of the cells was evaluated in our MTS-PES assay to assess their ability for in 384 situ reduction of the tetrazolium compound MTS. This cell dilution range revealed a 385 clear density-dependent step-wise difference in optical density (OD), roughly between 386 100 and 10,000 cells/well ( Figure 6A) . Also, a longer incubation time (3 days) of the 387 U87.ACE2 + cells returned a comparable result with maximum values plateauing at 388 12,500 cells/well, and minimum values below 500 cells/well. Next, the U87.ACE2 + cells 389 were exposed to a dilution range of SARS-CoV-2 (20A.EU2 strain), and CPE was 390 assessed spectrophotometrically. As depicted in Figure 6B , a clear difference in OD 391 between virus-infected and mock-infected control cells was obtained, in a reproducible 392 manner (4 replicate wells), and resulted in a virus concentration-dependent change in 393

OD-values ( Figure 6B) . Furthermore, the colorimetric read-out could be easily applied 394 to determine the cytotoxicity ( Figure 6C ) and antiviral activity (Figure 6D ) of 395

Remdesivir. Full protection of virus-exposed U87.ACE2 + cells was obtained with 396

Remdesivir at concentrations as low as 80 nM, whereas the next compound dilution 397 (16 nM) evoked a complete CPE. Based on these OD values an IC50 value of 35 nM 398 could be calculated for Remdesivir, which corresponded well with the value obtained 399 through RT-qPCR analysis (Figure 5C) . 400

In the context of the continuous identification of new circulating SARS-CoV-2 variants, 401 our CPE reduction assay with the U87.ACE2 + cells should also be applicable to new 402 arising SARS-CoV-2 mutants. We therefore exposed the U87.ACE2 + cells to different 403 SARS-CoV-2 variants of concern available in our laboratory (16). As shown in Figure  404 7A, our cells could be readily infected by all tested variants, including the recent 405 circulating Omicron variant (26). Furthermore, all these SARS-CoV-2 variants induced 406 strong CPE that could be exploited to evaluate antiviral compounds by our MTS-PES 407 assay. Interestingly, Remdesivir proved to remain active also in the Omicron-infected 408 U87.ACE2 + cells, although with at slightly higher IC50 value ( Figure 7B) . that ACE2 needs to be expressed abundantly before glioma cells become permissive 445 to SARS-CoV-2. Supplementary, our data also reveal that (temporarily) upregulation 446 of ACE2 in glioma cells (e.g., in some malignancies) might turn neuronal cells into 447 highly permissive target cells for SARS-CoV-2. Thus, the U87.ACE2 + cells might 448 represent useful tools to disentangle the entry and replication of SARS-CoV-2 in the 449

The viral spike protein of SARS-CoV-2 drives ACE2 receptor binding and subsequent 451 membrane fusion of the viral envelope with the cell membrane. However, in order to 452 initiate this membrane fusion reaction, the S protein needs to be proteolytic cleaved 453 upstream of its fusion peptide by an appropriate protease. Several different proteases 454 have been identified that can prime SARS-CoV-2 S, either at the plasma membrane 455 (TMPRSS2) or in endosomes/lysosomes (cathepsins) (3, 8, 42, 43) . This flexibility in 456 protease usage and entry route appears to be a consistent strategy used by 457 coronaviruses (2, 11). Thus, besides ACE2 expression viral tropism will also largely 22 depend on the availability of those cellular proteases, generating a cell type-459 dependency for SARS- 44) . The U87 glioblastoma cells used in our study 460 did express both TMPRSS2 and CTSB/L. Whereas the level of TMPRSS2 in the 461 U87.ACE2 + cells was low as compared to the lung epithelia-derived Calu-3 cell line 462 (often considered as a physiologically relevant cell type for SARS-CoV-2) (8), it might 463 still be sufficient to initiate cell surface SARS-CoV-2 entry. This is in contrast with the 464 widely-used Vero E6 cells which are human TMPRSS2-deficient, as confirmed by our 465 results. However, levels of CTSB were extremely high in the U87.ACE2 + cells, whereas 466 Vero E6 cells had nearly detectable CTSB, and vice versa, protein levels of CTSL were 467 high in Vero E6 cells and much lower in the U87.ACE2 + cells. These data suggest that 468 the U87.ACE2 + cells might accommodate an endosomal entry route for SARS-CoV-2, 469 and if so, that CTSB can also be a relevant cysteine protease for S priming. In that 470 perspective, the U87.ACE2 + cells can be considered as a valuable additional cell line 471 for further cathepsin studies in SARS-CoV-2 research. Furthermore, based on recent 472 reports of the current circulating Omicron variant, demonstrating that SARS-CoV-2 473

Omicron infection is not enhanced by TMPRSS2 but is largely mediated via the 474 endocytic pathway (12, 13), more attention should be given to the endosomal entry 475 route for SARS-CoV-2. Of note, our U87.ACE2 + cells remained highly permissive for 476 other SARS-CoV-2 variants of concern, including the Omicron variant. 477

Finally, one of the advantages of the human U87.ACE2 + cells (e.g., compared to Vero 478 E6 cells) is their ability to induce a rapid and full-blown CPE, a feature that is of great 479 value for an easy and clear-cut read-out in a CPE reduction assay. Thus, infection of Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al., 2021. SARS-CoV-2 535 Omicron variant shows less efficient replication and fusion activity when compared with 536 delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 

Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in 603 Human Brain Organoids

Non-permissive SARS-CoV-2 infection in human neurospheres

Single-Cell 609

Sequencing of Glioblastoma Reveals Central Nervous System Susceptibility to SARS-610

Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism

Model Virus Infection in Human Cells and Organoids

Infectability of human BrainSphere neurons suggests neurotropism of 617

SARS-CoV-2 targets neurons of 3D human brain organoids

SARS-CoV-2 622 infects human neural progenitor cells and brain organoids

Susceptibility of neuroblastoma and glioblastoma cell lines to SARS-CoV-2 infection

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Tissue 631 distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step 632 in understanding SARS pathogenesis

Coronavirus 635 membrane fusion mechanism offers a potential target for antiviral development

Targeting the viral-entry facilitators 638 of SARS-CoV-2 as a therapeutic strategy in COVID-19

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2

SARS-CoV with implications for clinical manifestations, transmissibility, and 643 laboratory studies of COVID-19: an observational study

approximately 8,000 analyzed cells. C) U87.ACE2 + cells were overlayed with 672 HEK293T cells either non-transfected (NT) or transfected (TF) with a plasmid encoding 673 for the SARS-CoV-2 spike protein. As an additional control, U87 (without ACE2) were 674 combined with TF HEK293T cells. Pictures were taken 24h after the co-cultivation of 675 both cell types (4X magnification). 676 U87.ACE2 + cells were exposed to different doses of SARS-CoV-2 (Wuhan strain). 690Samples were collected at 16 h post infection and 5,000 -6,000 cells were analyzed 691 by flow cytometry. Cells were stained for intracellular nucleoprotein (N) expression. 692Dot plots show N expression in noninfected (lower left quadrant) and infected (lower 693 right quadrant) cells. The numbers in each quadrant refer to the distribution of the cells 694 (i.e., percentage of total cell population). The dot plot in grey (left panel) represents the 695 noninfected cell control. B). U87.ACE2 + cells were exposed to SARS-CoV-2 (20A.EU2 696 33 strain; MOI 5) for 1 hour (indicated by grey boxed V). Next, cells were washed 697 extensively to remove unbound virus and were given fresh medium. Supernatant was 698 collected at the indicated time points and a duplex RT-qPCR was performed to quantify 699 the copy numbers of the N and E genes. The dotted horizontal line refers to the 700 background signal. For each sample, the average (mean ± SD) of two technical 701 replicates is given (n = 2), plotted on a log10 scale. 702 represents the noninfected cell control. B) U87.ACE2 + cells were exposed to SARS-711CoV-2 (Wuhan strain, MOI 0.3) for 2 h in absence (Virus control) or presence of 712 inhibitors (2 µM Remdesivir or 10 µg/ml antibody R001). Supernatant (= virus input) 713 was then removed, and cells were washed in PBS and given fresh medium. In the 714 conditions with the antiviral treatment, compound was administered together with the 715 virus, and administered again after the wash step. At day 2 p.i., supernatant was 716 collected and RT-qPCR was performed to quantify the copy numbers of the N gene 717 and the E gene. The dotted colored lines refer to the residual amount (background) of 718 virus that attached nonspecifically to the cells and was measured immediately after the 719 wash step (2 h p.i.). For each sample, the average (mean ± SD) of two technical 720 replicates is given (n = 2), plotted on a log10 scale. C) Same as in (B) but for a dilution 721 34 range of remdesivir. U87.ACE2 + cells were exposed to two different variants of concern 722 of SARS-CoV-2 (MOI 0.3), as indicated. RT-qPCR data of the N gene were used to 723 calculate the % inhibition of viral replication and to plot a concentration-response curve 724 for Remdesivir. The calculated IC50 value of Remdesivir for each virus strain is 725 indicated in the matching color. 726 concern and preserve remdesivir activity against Omicron. A) U87.ACE2 + cells 750 were exposed to a virus stock dilution range (1:10) of different SARS-CoV-2 variants 751 of concern (starting from a 10 1 x dilution), incubated for 4 days and analyzed by MTS-752 PES. The blue dotted line represents the cell control (CC) and the dotted black line 753 represents the OD value measured for medium only. concern and preserve remdesivir activity against Omicron. A) U87.ACE2 + cells 875 were exposed to a virus stock dilution range (1:10) of different SARS-CoV-2 variants 876 49 of concern (starting from a 10 1 x dilution), incubated for 4 days and analyzed by MTS-877 PES. The blue dotted line represents the cell control (CC) and the dotted black line 878 represents the OD value measured for medium only. Graphs show optical density (OD) 879 values (mean ± SD; n = 2). B) U87.ACE2 + cells were infected with SARS-CoV-2 880 (Omicron strain, MOI 0.08) in absence or presence of Remdesivir, incubated for 4 days 881 and analyzed by MTS-PES. OD values were used to calculate the % inhibition of viral 882 replication and to plot a concentration-response curve for Remdesivir. Values are 883 mean ± SD from 2 biological replicates (n = 2). 884